Journey with AxxessBio:
Stay informed with our latest news, press releases and shared milestones

Latest News and Releases

AxxessBio and PTC Therapeutics introduce Translarna™ for Duchenne muscular dystrophy and Upstaza™ for AADC Deficiency in Southeast Asia

On 1st November 2023, PTC Therapeutics International Limited, granted exclusive distribution rights to AxxessBio in several countries in Southeast Asia for Translarna™ (ataluren) and a service agreement for Upstaza™ (eladocagene exuparvovec). Translarna™ is indicated for the treatment of Duchenne muscular dystrophy (DMD), resulting from a nonsense mutation in the dystrophin

Read More »

Interested in Partnering Up?

At AxxessBio, we are continuously looking for partnerships to bring new innovative therapies for patients all around Asia